Cogent Biosciences, Inc.

Quick facts

Phase 3 pipeline

• CGT9486 · Oncology
  CGT9486 is a selective tyrosine kinase inhibitor that targets FLT3, a receptor implicated in acute myeloid leukemia and other hematologic malignancies.
• CGT9486 plus sunitinib · Oncology
  CGT9486 is a selective FLT3 inhibitor combined with sunitinib, a multi-targeted tyrosine kinase inhibitor, to block FLT3 and PDGFR signaling in acute myeloid leukemia.

Phase 1 pipeline

• CGT4255
• CGT4859
• CGT6297

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Cogent Biosciences, Inc. portfolio CI brief
• Cogent Biosciences, Inc. pipeline updates RSS